# System1 Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/system1-biosciences

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.system1.bio
- Total disclosed funding: $25M
- Latest round: Series A (Aug 2, 2018)
- Investors on record: 11

## About

System1 Biosciences, Inc. is a biotechnology firm specializing in innovative solutions for drug discovery and development, leveraging advanced technologies for therapeutic advancements.Founded in 2017 in San Francisco, US, System1 Biosciences, Inc. focuses on transforming drug discovery processes. The company has not undergone any significant pivots. Co-founded by Saul Kato and Sean Escola, it has secured a total of USD 25.00 mn in funding through a Series A round on August 2, 2018, with investors including CRV and Pfizer Venture Investments. The company maintains its headquarters in San Francisco and has executed one notable deal.System1 Biosciences, Inc. offers advanced digital solutions for drug discovery, focusing on high-throughput screening and data analytics to support pharmaceutical research. Its services are tailored for biotech and pharmaceutical companies, enabling them to optimize their drug development pipelines. The company's clientele includes research institutions and pharmaceutical entities, with an emphasis on enhancing research efficiency and accuracy in drug testing and validation.The company generates revenue through a project-based model, charging clients for its specialized services in drug discovery. Clients select service packages based on their specific research needs and project scopes, allowing for a flexible pricing strategy that accommodates various budget levels. System1 Biosciences serves a diverse range of pharmaceutical and biotech companies, establishing ongoing collaborative partnerships that foster sustained revenue generation.System1 Biosciences, Inc. plans to expand its product offerings with new platforms aimed at integrating artificial intelligence in drug discovery processes, targeting a rollout by late 2023. Geographic expansion into European markets is also on the agenda, aiming for implementation in 2024. The recent Series A funding of USD 25.00 mn will be utilized to support these initiatives, enhancing technology development and market entry strategies.

## Funding rounds

- Series A, Aug 2, 2018, $25M — CRV, Alexandria Venture Investments, Pfizer Venture Investments, Webb Investment Network, The Longevity Fund, Dolby Family Ventures, Liquid 2 Ventures, Boom Capital Management, Kinled Holding, Riot Ventures, Wilmot Ventures

## Investors

- CRV (https://capitalatlas.ai/funds/crv) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Webb Investment Network (https://capitalatlas.ai/funds/webb-investment-network) — Series A
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A
- Dolby Family Ventures (https://capitalatlas.ai/funds/dolby-family-ventures) — Series A
- Liquid 2 Ventures (https://capitalatlas.ai/funds/liquid-2-ventures) — Series A
- Boom Capital Management (https://capitalatlas.ai/funds/boom-capital-management) — Series A
- Kinled Holding — Series A
- Riot Ventures (https://capitalatlas.ai/funds/riot-ventures) — Series A
- Wilmot Ventures (https://capitalatlas.ai/funds/wilmot-ventures) — Series A